Soluble HLA-G: A Novel Marker in Acute Myeloid Leukemia Patients

Primary tabs

Acta Medica International,2017,4,1,51-55.
Published:November 2016
Type:Original Article

Soluble HLA-G: A Novel Marker in Acute Myeloid Leukemia Patients

Nahla Abdel Moneim Hamed1*, Nabil El Halawani1, Dalia Nafea1, Mohamed Abd El Rahman2, Ahmed Kasber3

1Department of Clinical Haematology, Faculty of Medicine, Alexandria University, Alexandria, EGYPT.

2Department of Clinical Pathology, Military Medical Academy, Alexandria, EGYPT.

3Department of Clinical Haematology, Military Medical Academy, Alexandria, EGYPT.

Abstract:

Objective: To study soluble HLA-G (sHLA-G) in Egyptian acute myeloid leukemia (AML) patients. HLA-G is speculated to be a tumor-driven immune escape mechanism. In addition, it might be a promising target for future immune therapeutic approaches.

Methods: Thirty AML patients and 15 healthy controls of matched age and sex were the subject of the study. sHLA-G was done to all patients and controls by ELISA.

Results: Statistically significant increase in sHLA-G level was present in AML patients compared to controls, being higher in relapsed cases. HLA-G levels was correlated to bone marrow blast percentages but not affected by age, gender, WBCs or response to chemotherapy. HLA-G had a sensitivity of 100% and a specificity of 62% to detect AML cases.

Conclusion: HLA-G may be an additional marker for AML especially relapsed cases.

Laboratory Findings in the Studied Groups